Bristol-Myers Squibb Co.’s decision to hold off launching Zeposia, its newly approved multiple sclerosis treatment, underscores how disruptive the COVID-19 pandemic is to a trillion-dollar industry that relies heavily on collaborative working and meeting milestones that satiate investors.